全文获取类型
收费全文 | 64377篇 |
免费 | 4182篇 |
国内免费 | 177篇 |
专业分类
耳鼻咽喉 | 928篇 |
儿科学 | 1637篇 |
妇产科学 | 1570篇 |
基础医学 | 8582篇 |
口腔科学 | 3850篇 |
临床医学 | 5195篇 |
内科学 | 13741篇 |
皮肤病学 | 1597篇 |
神经病学 | 6037篇 |
特种医学 | 1549篇 |
外国民族医学 | 3篇 |
外科学 | 7642篇 |
综合类 | 556篇 |
一般理论 | 23篇 |
预防医学 | 6128篇 |
眼科学 | 1490篇 |
药学 | 4997篇 |
中国医学 | 369篇 |
肿瘤学 | 2842篇 |
出版年
2023年 | 427篇 |
2022年 | 427篇 |
2021年 | 1694篇 |
2020年 | 1204篇 |
2019年 | 1733篇 |
2018年 | 2210篇 |
2017年 | 1480篇 |
2016年 | 1585篇 |
2015年 | 1792篇 |
2014年 | 2433篇 |
2013年 | 3219篇 |
2012年 | 4613篇 |
2011年 | 4864篇 |
2010年 | 2615篇 |
2009年 | 2195篇 |
2008年 | 3744篇 |
2007年 | 3654篇 |
2006年 | 3385篇 |
2005年 | 3128篇 |
2004年 | 2830篇 |
2003年 | 2438篇 |
2002年 | 2260篇 |
2001年 | 1569篇 |
2000年 | 1541篇 |
1999年 | 1247篇 |
1998年 | 394篇 |
1997年 | 311篇 |
1996年 | 273篇 |
1995年 | 281篇 |
1994年 | 288篇 |
1993年 | 228篇 |
1992年 | 704篇 |
1991年 | 668篇 |
1990年 | 635篇 |
1989年 | 518篇 |
1988年 | 539篇 |
1987年 | 485篇 |
1986年 | 473篇 |
1985年 | 411篇 |
1984年 | 345篇 |
1983年 | 318篇 |
1982年 | 208篇 |
1981年 | 208篇 |
1980年 | 185篇 |
1979年 | 348篇 |
1978年 | 235篇 |
1976年 | 188篇 |
1975年 | 210篇 |
1974年 | 212篇 |
1973年 | 178篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Ruscitti Piero Di Cola Ilenia Berardicurti Onorina Conforti Alessandro Iacono Daniela Pantano Ilenia Rozza Gelsomina Rossi Silvia De Stefano Ludovico Balduzzi Silvia Vitale Antonio Caso Francesco Costa Luisa Prete Marcella Navarini Luca Atzeni Fabiola Guggino Giuliana Perosa Federico Cantarini Luca Frediani Bruno Montecucco Carlomaurizio Ciccia Francesco Giacomelli Roberto Cipriani Paola 《Clinical rheumatology》2022,41(11):3597-3597
Clinical Rheumatology - 相似文献
2.
Tiago Ribeiro Leal Larissa Chaves Morais de Lima rick Tssio Barbosa Neves Maria Jacinta Arêa Leo Lopes Araújo Arruda Matheus Frana Perazzo Saul Martins Paiva Júnia Maria Serra-Negra Fernanda de Morais Ferreira Ana Flvia Granville-Garcia 《International journal of paediatric dentistry / the British Paedodontic Society [and] the International Association of Dentistry for Children》2022,32(1):22-30
3.
4.
Marc Evans MD Susanne Engberg MD Mads Faurby MSc João Diogo Da Rocha Fernandes MSc Pollyanna Hudson MSc William Polonsky PhD 《Diabetes, obesity & metabolism》2022,24(3):377-390
We designed a systematic literature review to identify available evidence on adherence to and persistence with antidiabetic medication in people with type 2 diabetes (T2D). Electronic screening and congress searches identified real-world noninterventional studies (published between 2010 and October 2020) reporting estimates of adherence to and persistence with antidiabetic medication in adults with T2D, and associations with glycaemic control, microvascular and/or macrovascular complications, hospitalizations and healthcare costs. Ninety-two relevant studies were identified, the majority of which were retrospective and reported US data. The proportions of patients considered adherent (median [range] 51.2% [9.4%-84.3%]) or persistent (median [range] 47.7% [16.9%-94.0%]) varied widely across studies. Multiple studies reported an association between greater adherence/persistence and greater reductions in glycated haemoglobin levels. Better adherence/persistence was associated with fewer microvascular and/or macrovascular outcomes, although there was little consistency across studies in terms of which outcomes were improved. More adherent and more persistent patients were typically less likely to be hospitalized or to have emergency department visits/admissions and spent fewer days in hospital annually than less adherent/persistent patients. Greater adherence and persistence were generally associated with lower hospitalization costs, higher pharmacy costs and lower or budget-neutral total healthcare costs compared with lower adherence/persistence. In conclusion, better adherence and persistence in people with T2D is associated with lower rates of microvascular and/or macrovascular outcomes and inpatient hospitalization, and lower or budget-neutral total healthcare expenditure. Education and treatment strategies to address suboptimal adherence and persistence are needed to improve clinical and economic outcomes. 相似文献
5.
Francisco José Álvarez García María José Cilleruelo Ortega Javier Álvarez Aldeán María Garcés-Sánchez Nuria García Sánchez Elisa Garrote Llanos Ángel Hernández Merino Antonio Iofrío de Arce Abián Montesdeoca Melián María Luisa Navarro Gómez Jesús Ruiz-Contreras 《Anales de pediatría (Barcelona, Spain : 2003)》2021,94(1):53.e1-53.e10
The CAV-AEP annually publishes the immunisation schedule considered optimal for all children and adolescent resident in Spain, taking into account the available evidence.The 2 + 1 schedule is recommended (2, 4, and 11 months) with hexavalent vaccines (DTPa-VPI-Hib-HB) and with 13-valent pneumococcal conjugate.A 6-year booster is recommended, preferably with DTPa (if available), with a dose of polio for those who received 2 + 1 schemes, as well as vaccination with Tdpa in adolescents and in each pregnancy, preferably between 27 and 32 weeks.Rotavirus vaccine should be systematic for all infants.Meningococcal B vaccine, with a 2 + 1 schedule, should be included in routine calendar.In addition to the inclusion of the conjugated tetravalent meningococcal vaccine (MenACWY) at 12 years of age with catch up to 18 years, inclusive, the CAV recommends this vaccine to be also included at 12 months of age, replacing MenC. Likewise, it is recommended in those over 6 weeks of age with risk factors or who travel to countries with a high incidence of these serogroups.Two-dose schedules for triple viral (12 months and 3-4 years) and varicella (15 months and 3-4 years) will be used. The second dose could be applied as a tetraviral vaccine.Universal systematic vaccination against HPV is recommended, regardless of gender, preferably at 12 years, and greater effort should be made to improve coverage. The 9 genotype extends coverage for both genders. 相似文献
6.
7.
Buket Bakan Fatih Oltulu Yeliz Y?ld?r?m Altu? Yava?o?lu Sinan Akg?l Nefise ülkü Karabay Yava?o?lu 《Arhiv za higijenu rada i toksikologiju》2023,74(3):207
The aim of this safety study in mice was to determine in vivo toxicity and biodistribution potential of a single and multiple doses of L-glutamic acid-g-p(HEMA) polymeric nanoparticles as a drug delivery system. The single dose did not cause any lethal effect, and its acute oral LD50 was >2.000 mg/kg body weight (bw). Multiple doses (25, 50, or 100 mg/kg bw) given over 28 days resulted in no significant differences in body and relative organ weights compared to control. These results are supported by biochemical and histological findings. Moreover, nanoparticle exposure did not result in statistically significant differences in micronucleus counts in bone marrow cells compared to control. Nanoparticle distribution was time-dependent, and they reached the organs and even bone marrow by hour 6, as established by ex vivo imaging with the IVIS® spectrum imaging system. In conclusion, L-glutamic acid-g-p(HEMA) polymeric nanoparticles appear biocompatible and have a potential use as a drug delivery system.KEY WORDS: biocompatibility, blood biochemistry, genotoxicity, histology, in vivo toxicity, micronucleus test, polymers 相似文献
8.
Chalub Lucas Orbolato Nunes Gabriel Pereira Ferrisse Túlio Morandin Strazzi-Sahyon Henrico Badaoui Dos Santos Paulo Henrique Gomes-Filho João Eduardo Cintra Luciano Tavares Angelo Sivieri-Araujo Gustavo 《Clinical oral investigations》2022,26(4):3343-3356
Clinical Oral Investigations - The objective of this systematic review and meta-analysis (SRM) was to answer the question whether the use of ultrasonic irrigation (UI) results in less postoperative... 相似文献
9.
10.
Penelas Alice Gonçalves da Silva Eduardo Moreira Fedozzi Julia Mattos Alves Amanda Cypriano Orem Paulo Roberto Barros Poskus Laiza Tatiana Feitosa Victor Pinheiro Guimarães José Guilherme Antunes 《Odontology / the Society of the Nippon Dental University》2022,110(3):569-576
Odontology - This study aimed at evaluating the influence of glass-fiber post (GFP) relining with composites of different opacities on resin cement layer thickness (CLT), bond strength (BS) to root... 相似文献